Text Size

The Effectiveness of Idazoxan in Treating TRD

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00294944
First received: February 19, 2006
Last updated: January 28, 2008
Last verified: January 2008
History of Changes
  Purpose

Assessing the effectiveness of Idazoxan as a treatment for depressive patients who did not respond to treatment with SSRI


Condition Intervention Phase
Major Depressive Disorder
 Drug: Idazoxan
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind

Resource links provided by NLM:

MedlinePlus related topics: Depression
U.S. FDA Resources

Further study details as provided by Sheba Medical Center:

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • MDD patients
  • Did not respond to at least one treatment of 4-6 weeks of SSRI in adequate dose
  • In or out patients

Exclusion Criteria:

  • Psychotic symptoms
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00294944

Locations
Israel
Chaim Sheba Medical Center
Ramat-Gan, Israel, 52621
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Joseph Zohar, MD Sheba Medical Center
  More Information

No publications provided

Responsible Party: Prof. Joseph Zohar, Chaim Sheba Medical Center
ClinicalTrials.gov Identifier: NCT00294944     History of Changes
Other Study ID Numbers: SHEBA-05-3911-JZ-CTIL
Study First Received: February 19, 2006
Last Updated: January 28, 2008
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Idazoxan
Adrenergic alpha-2 Receptor Antagonists
 Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 16, 2012